title: Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas.
abstract: The Janus kinase 2 (JAK2)-signal transducers and activators of transcription (STAT) pathway plays an important role in hematological malignancies. Mutations and translocations of the JAK2 gene, mapped at 9p24, lead to constitutive activation of JAK2 and its downstream targets. The presence of JAK2 mutations in lymphomas has been addressed in larger cohorts, but there are little systemic data on numerical and structural JAK2 aberrations in lymphoid neoplasms. To study the molecular epidemiology of these aberrations and the consecutive activation of the JAK2-STAT pathway in lymphomas, we examined 527 cases, covering the most common entities, in a tissue microarray by fluorescent in situ hybridization with breakable JAK2 probes, and immunohistochemistry for phosphorylated JAK2 (pJAK2) and its preferred downstream pSTAT3 and pSTAT5. 9p24 gains were detected in 6/17 (35%) primary mediastinal B-cell lymphomas (PMBCLs), 25/77 (33%) Hodgkin's lymphomas (HLs), 3/16 (19%) angioimmunoblastic T-cell lymphomas (AILTs) and 1/5 ALK1(+) anaplastic large cell lymphomas (ALCLs); breaks were observed only in three cases. pJAK2 expression was most prevalent in PMBCL, peripheral T-cell lymphomas and HL. pSTAT3 predominated in ALCLs, HLs, AILTs, PMBCLs and peripheral T-cell lymphomas. pSTAT5 expression was detected frequently in follicular lymphomas, diffuse large B-cell lymphomas and AILTs. 9p24 gains correlated with increased proportions of tumor cells expressing pJAK2 (P=0.002) and pSTAT3 (P=0.001). In follicular lymphomas, concomitant expression of pJAK2 and pSTAT5 was linked to better prognosis, whereas expression of pSTAT3 in nongerminal center-like diffuse large B-cell lymphomas could identify a patient group with an inferior outcome. Our findings stress that despite the rarity of activating JAK2 mutations in lymphomas, JAK2 is recurrently targeted by numerical, and rarely by structural, genetic aberrations in distinct lymphoma subtypes and that JAK2-STAT pathway may play a role in lymphomagenesis.
authors.affiliation: Department of Pathology, University of Basel, Basel, Switzerland.
authors.forename: Cecile
authors.initials: C
authors.lastname: Meier
authors.forename: Sylvia
authors.initials: S
authors.lastname: Hoeller
authors.forename: Caroline
authors.initials: C
authors.lastname: Bourgau
authors.forename: Petra
authors.initials: P
authors.lastname: Hirschmann
authors.forename: Juerg
authors.initials: J
authors.lastname: Schwaller
authors.forename: Philip
authors.initials: P
authors.lastname: Went
authors.forename: Stefano A
authors.initials: SA
authors.lastname: Pileri
authors.forename: Andreas
authors.initials: A
authors.lastname: Reiter
authors.forename: Stephan
authors.initials: S
authors.lastname: Dirnhofer
authors.forename: Alexandar
authors.initials: A
authors.lastname: Tzankov
mesh_terms: D002869:Chromosome Aberrations; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D053614:Janus Kinase 2 / Q000235:genetics* / Q000378:metabolism; D008223:Lymphoma / Q000235:genetics* / Q000378:metabolism* / Q000401:mortality; D009154:Mutation; D011379:Prognosis; D012372:ROC Curve; D050791:STAT Transcription Factors / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology*; D016019:Survival Analysis; D046888:Tissue Array Analysis
chemical_list: D050791:STAT Transcription Factors; C507924:JAK2 protein, human; D053614:Janus Kinase 2